These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 19747132)
1. Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer. Rossi A; Maione P; Ferrara ML; Sacco PC; Schettino C; Bareschino MA; Gridelli C Curr Med Chem; 2009; 16(30):3919-30. PubMed ID: 19747132 [TBL] [Abstract][Full Text] [Related]
2. Recent developments of targeted therapies in the treatment of non-small cell lung cancer. Rossi A; Maione P; Colantuoni G; Ferrara C; Rossi E; Guerriero C; Nicolella D; Falanga M; Palazzolo G; Gridelli C Curr Drug Discov Technol; 2009 Jun; 6(2):91-102. PubMed ID: 19519336 [TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy. Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044 [TBL] [Abstract][Full Text] [Related]
4. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Cabebe E; Wakelee H Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832 [TBL] [Abstract][Full Text] [Related]
5. New antiangiogenetic agents and non-small cell lung cancer. Gridelli C; Rossi A; Maione P Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002 [TBL] [Abstract][Full Text] [Related]
6. [Targeted therapies in the treatment of non-small cell lung cancer]. De Grève J; Decoster L; Van Meerbeek J; Vermeij J; Teugels E; Schallier D Bull Cancer; 2008 Mar; 95(3):358-64. PubMed ID: 18390417 [TBL] [Abstract][Full Text] [Related]
7. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. Horn L; Sandler AB Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948 [TBL] [Abstract][Full Text] [Related]
8. Targeting angiogenesis for treatment of NSCLC brain metastases. Schettino C; Bareschino MA; Rossi A; Maione P; Sacco PC; Colantuoni G; Rossi E; Gridelli C Curr Cancer Drug Targets; 2012 Mar; 12(3):289-99. PubMed ID: 22229249 [TBL] [Abstract][Full Text] [Related]
9. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. Gridelli C; Maione P; Rossi A; De Marinis F Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612 [TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Aggarwal C; Somaiah N; Simon G Cancer Biol Ther; 2012 Mar; 13(5):247-63. PubMed ID: 22481432 [TBL] [Abstract][Full Text] [Related]
11. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548 [TBL] [Abstract][Full Text] [Related]
19. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients. Kurzrock R; Stewart DJ Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520 [TBL] [Abstract][Full Text] [Related]